Status:

COMPLETED

Isoleucine Intake and Intermediary Metabolism in Type 2 Diabetes

Lead Sponsor:

Texas A&M University

Conditions:

Type 2 Diabetes

Eligibility:

All Genders

45-84 years

Phase:

NA

Brief Summary

The primary objective of this study is to determine the mechanism of reduced branched-chain amino acid (BCAA) oxidation to propionyl CoA and isoleucine intake can affect TCA cycle function in obese in...

Detailed Description

Defects in mitochondrial β-oxidation and branched chain amino acid (BCAA) oxidation are associated with type 2 diabetes (T2D) and other conditions such as Huntington's disease and maple syrup urine di...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Age: 45-84 years old, inclusive
  • Clinical diagnosis with type-II diabetes (Diabetics subjects only) and oral glucose lowering medication or insulin
  • Stable body-weight (± 5%) for the past 3 months
  • Body Mass Index (BMI): 28 kg/m2 or higher
  • Subject is judged to be in satisfactory health based on medical history, physical examination, and laboratory screening evaluations.
  • Ability to walk, sit down and stand up independently
  • Ability to lie in supine or elevated position for up to 10 hours
  • Willingness and ability to comply with the protocol
  • Exclusion criteria:
  • Subject is expected to have surgery within one-month of screening
  • Subject is currently participating or has participated in a study with an investigational compound or device within 30 days of signing the informed consent.
  • Active dependence of alcohol or drugs
  • Diagnosed and active treatment of Type 1 Diabetes Mellitus
  • Medication: Use of substances known to influence protein metabolism: antibiotics within 3 weeks prior to the study visit, current use of corticosteroids, growth hormone, testosterone, estrogen, immunosuppressant, blood thinners, or insulin.
  • Adherence to a weight loss diet.
  • (Possible) pregnancy

Exclusion

    Key Trial Info

    Start Date :

    May 30 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    March 2 2020

    Estimated Enrollment :

    38 Patients enrolled

    Trial Details

    Trial ID

    NCT04461236

    Start Date

    May 30 2019

    End Date

    March 2 2020

    Last Update

    February 3 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Texas A&M University CTRAL

    College Station, Texas, United States, 77845-4253